Peptide
N-Acetyl Selank
SaveAn N-acetylated form of selank designed for improved intranasal bioavailability and resistance to enzymatic degradation.
Quick verdict
Based on the selank platform with theoretical pharmacokinetic improvements. Specific data on this acetylated form are very limited.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Extrapolated from selank literature. N-acetylation is a common peptide modification to improve stability. Specific comparative data are lacking.
Benefits
- Potentially improved nasal bioavailability
- Anxiolytic effects extrapolated from selank data
- Enhanced enzymatic stability theorized
Dosage notes
Community protocols mirror selank dosing: 200–600 mcg intranasally. Not clinically validated for this form.
Side effects
- Nasal irritation
- Fatigue
- Headache
Who should be cautious
Not approved in Western countries. Even the parent compound selank is only approved in Russia.
What this page cannot tell you
Benefits are inferred from selank data. No independent validation of the acetylated form.
Leaderboard scores
- Anxiety30
- Stress25
- Focus20
Write a review
Sign in to write a review.